Meihua Medical faces Nasdaq delisting, moves to OTC

Meihua International Medical Technologies reports that Nasdaq has moved forward with delisting its securities.

Rhea-AI Filing Summary

Meihua International Medical Technologies reports that Nasdaq has moved forward with delisting its securities. Nasdaq staff initially determined to delist the shares in December 2025, and trading of the Company’s class A ordinary shares was suspended and moved to the OTC Marketplace under the symbol “MHUAF” on December 9, 2025.

The Company appealed and attended a hearing before a Nasdaq Hearings Panel on January 27, 2026, but on February 24, 2026 the Panel denied the request to reinstate trading and determined to delist the securities. On March 2, 2026, the Company requested further review of the Panel’s delisting decision by the Nasdaq Listing and Hearing Review Council.

Positive

• None.

Negative

• Nasdaq delisting decision upheld by Hearings Panel, with the Company’s class A ordinary shares suspended from Nasdaq and trading moved to the OTC Marketplace under the symbol “MHUAF,” reducing major-exchange presence while a further internal Nasdaq review is pending.

Insights

Equity markets and listing standards analyst

Nasdaq has upheld a delisting decision while the company seeks one final internal review.

Meihua International Medical Technologies explains that its class A ordinary shares were suspended from Nasdaq and began trading on the OTC Marketplace under the symbol “MHUAF” after a Nasdaq staff delisting determination under Listing Rule 5815(c).

The Company pursued an appeal, but a Nasdaq Hearings Panel denied reinstatement of trading and determined to delist the securities on February 24, 2026. This keeps the shares off a major exchange and instead on an over-the-counter venue, which typically has different liquidity and visibility characteristics.

On March 2, 2026, the Company requested that the Nasdaq Listing and Hearing Review Council review the Panel’s decision. The ultimate listing outcome depends on that council’s review, based on the process described.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq action does Meihua International Medical Technologies (MHUA) report in this 6-K?

Meihua International Medical Technologies reports that Nasdaq staff determined to delist its securities under Listing Rule 5815(c). A subsequent Nasdaq Hearings Panel denied the Company’s appeal to reinstate trading and determined to delist the Company’s securities.

Where do Meihua International Medical Technologies shares trade after the Nasdaq suspension?

After Nasdaq suspended trading, the Company’s class A ordinary shares began trading on the OTC Marketplace under the symbol “MHUAF” on December 9, 2025. This change followed Nasdaq staff’s initial decision to delist the securities under its listing rules.

What happened at Meihua International Medical Technologies’ Nasdaq Hearings Panel appeal?

The Company attended a hearing before a Nasdaq Hearings Panel on January 27, 2026 to appeal the delisting determination. On February 24, 2026, Nasdaq notified the Company that the Panel denied reinstating trading and determined to delist the securities.

How is Meihua International Medical Technologies responding to Nasdaq’s delisting decision?

On March 2, 2026, Meihua International Medical Technologies requested that the Nasdaq Listing and Hearing Review Council review the Hearings Panel’s decision. This step seeks further internal Nasdaq review of the determination to delist the Company’s securities.

When did Meihua International Medical Technologies first receive notice of Nasdaq’s delisting determination?

The Company first received a notice from Nasdaq on December 2, 2025 stating that Nasdaq staff had determined to delist its securities. That notice was based on Nasdaq’s authority under Listing Rule 5815(c), according to the Company’s description.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission file number 001-41291

Meihua International Medical Technologies Co., Ltd.

(Translation of registrant’s name into English)

88 Tongda Road, Touqiao Town

Guangling District, Yangzhou, 225000

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒    Form 40-F  ☐

Nasdaq Delisting Decision

As previously disclosed, Meihua International Medical Technologies Co., Ltd. (the “Company”) received a notice from The Nasdaq Stock Market (the “Nasdaq”) on December 2, 2025, notifying the Company that the Nasdaq staff had determined to delist the Company’s securities from the Nasdaq in accordance with its authority under Nasdaq Listing Rule 5815(c). The Company’s class A ordinary shares were subsequently suspended from trading on Nasdaq and started trading on the OTC Marketplace under the symbol “MHUAF” on December 9, 2025.

On January 27, 2026, the Company attended a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the delisting determination.

On February 24, 2026, the Company received a notice from Nasdaq, notifying the Company that the Panel had determined to deny the Company’s request to reinstate trading on Nasdaq and determined to delist the Company’s securities.  

On March 2, 2026, the Company requested the Nasdaq Listing and Hearing Review Council to review the Panel’s delisting decision.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Meihua International Medical Technologies Co., Ltd.
By:	/s/ Leyi Lee
Name:	Leyi Lee
Title:	Chief Executive Officer
Date: March 2, 2026

2